文献速递消化内镜消化道肿瘤与早癌肝病

肝硬化伴食管胃静脉曲张患者上消化道早癌或癌前病变的内镜黏膜下剥离术:中国大型三级中心10年经验

Endoscopic submucosal dissection for early cancers or precancerous lesions of the upper GI tract in cirrhotic patients with esophagogastric varices: 10-year experience from a large tertiary center in China.
PubMed 文献 · Gastrointest Endosc · 2023-01-16

该研究回顾性纳入2012年1月至2021年12月本中心15例肝硬化伴食管胃静脉曲张、因上消化道早癌或癌前病变接受内镜黏膜下剥离术的患者,分析其临床特征、内镜表现、治疗方法、不良事件及随访数据。结果显示R0切除率为100%,无患者肝功能恶化,仅2例发热和2例术后出血,中位随访27个月期间1例食管高级别上皮内瘤变在19个月时复发,无因手术、肝功能损伤或消化道肿瘤本身导致的死亡。作者认为内镜黏膜下剥离术对此类患者有效且安全,个体化临床治疗策略使严重不良事件发生率很低。

要点

  • 15例肝硬化伴食管胃静脉曲张患者接受内镜黏膜下剥离术,R0切除率100%。
  • 仅2例发热、2例术后出血,无患者肝功能恶化。
  • 中位随访27个月,1例食管高级别上皮内瘤变在19个月时复发。

核心结论

  • 作者认为内镜黏膜下剥离术是肝硬化伴食管胃静脉曲张患者上消化道早癌或癌前病变的有效且安全治疗方法。
  • 作者认为个体化临床治疗策略的发展使严重不良事件发生率很低。

研究设计与样本

  • 回顾性纳入2012年1月至2021年12月本中心15例肝硬化伴食管胃静脉曲张、因上消化道早癌或癌前病变接受内镜黏膜下剥离术的患者。
  • 分析临床特征、内镜表现、治疗方法、不良事件及随访数据。

主要发现

  • 15例患者中1例血小板计数<30×1000/mm3。
  • 食管胃静脉曲张状态:5例未治疗,1例内镜黏膜下剥离术后治疗,6例术前治疗,1例术前及术中治疗,2例术中治疗。
  • R0切除率为100%;16处黏膜病变中15处为内镜切除出血(ERB)-0或ERB-c1,1处为ERB-c2。
  • 无患者出现肝功能恶化;唯一不良事件为2例发热和2例术后出血。
  • 中位随访27个月,1例食管高级别上皮内瘤变在19个月时复发;无因内镜黏膜下剥离术操作、肝功能损伤或消化道肿瘤本身导致的死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Treatment strategies for early cancers or precancerous lesions of the upper GI tract in patients with cirrhosis and esophagogastric varices (EGVs) are complicated and risky. The aim of this study was to assess the efficacy and safety of endoscopic submucosal dissection (ESD) in the treatment of such patients and explore optimal treatment strategies. METHODS: We retrospectively enrolled 15 patients with cirrhosis and EGV who underwent ESD for early cancers or precancerous lesions of the upper GI tract from January 2012 to December 2021 at our center. Clinical features, endoscopic findings, treatment methods, adverse events, and follow-up data were analyzed. RESULTS: Of the 15 patients, 1 had a platelet count <30 × 1000/mm3. Five were untreated for EGV, 1 was treated after ESD, 6 were treated before ESD, 1 was treated before and during ESD, and 2 were treated during ESD. The R0 resection rate was 100%. Of the 16 mucosal lesions, 15 were endoscopic resection bleeding (ERB)-0 or ERB-c1, and 1 was ERB-c2. No patient experienced deterioration in liver function. The only adverse events were fever in 2 patients and postoperative bleeding in 2 patients. During a median follow-up of 27 months, 1 patient's esophageal high-grade dysplasia recurred at 19 months. No death resulted from the ESD procedure, liver function injury, or GI tumor itself. CONCLUSIONS: ESD is an effective and safe treatment for early cancers or precancerous lesions of the upper GI tract in patients with cirrhosis and EGV. The incidence of severe adverse events is very low due to the development of individualized clinical treatment strategies.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Zhang S, Liu YD, Chai NL, et al. Endoscopic submucosal dissection for early cancers or precancerous lesions of the upper GI tract in cirrhotic patients with esophagogastric varices: 10-year experience from a large tertiary center in China. Gastrointest Endosc. 2023. PMID: 36657608. doi:10.1016/j.gie.2023.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。